CpG oligonucleotides as vaccine adjuvants
N Kayraklioglu, B Horuluoglu, DM Klinman - DNA Vaccines: Methods and …, 2021 - Springer
CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically
designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid …
designed to stimulate Toll-like receptor 9. TLR9 is expressed on human plasmacytoid …
Recent progress concerning CpG DNA and its use as a vaccine adjuvant
H Shirota, DM Klinman - Expert review of vaccines, 2014 - Taylor & Francis
CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to
specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding …
specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding …
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
J Scheiermann, DM Klinman - Vaccine, 2014 - Elsevier
Synthetic oligonucleotides (ODN) that express unmethylated “CpG motifs” trigger cells that
express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells …
express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells …
CpG DNA as a vaccine adjuvant
C Bode, G Zhao, F Steinhagen, T Kinjo… - Expert review of …, 2011 - Taylor & Francis
Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells
that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) …
that express Toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells) …
Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides
G Mutwiri, LA Babiuk - Advanced drug delivery reviews, 2009 - Elsevier
CpG oligodeoxynucleotides (ODN) activate the immune system and are promising
immunotherapeutic agents against infectious diseases, allergy/asthma and cancer. It has …
immunotherapeutic agents against infectious diseases, allergy/asthma and cancer. It has …
CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer
Toll-like receptors (TLRs) are part of the innate immune system, and they belong to the
pattern recognition receptors (PRR) family. The PRR family is designed to recognize and …
pattern recognition receptors (PRR) family. The PRR family is designed to recognize and …
Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides
Unmethylated CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides activate
immune cells that express Toll-like Receptor 9. Activation through this receptor triggers …
immune cells that express Toll-like Receptor 9. Activation through this receptor triggers …
Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation
M Jurk, J Vollmer - BioDrugs, 2007 - Springer
Vertebrate toll-like receptors (TLRs) sense invading pathogens by recognizing bacterial and
viral structures and, as a result, activate innate and adaptive immune responses. Ten human …
viral structures and, as a result, activate innate and adaptive immune responses. Ten human …
Characterization of suppressive oligodeoxynucleotides that inhibit Toll‐like receptor‐9‐mediated activation of innate immunity
M Peter, K Bode, GB Lipford, F Eberle, K Heeg… - …, 2008 - Wiley Online Library
Synthetic oligodeoxynucleotides containing unmethylated CpG sequences (CpG‐ODNs)
stimulate Toll‐like receptor‐9 (TLR‐9), thereby activating innate immunity. Stimulatory CpG …
stimulate Toll‐like receptor‐9 (TLR‐9), thereby activating innate immunity. Stimulatory CpG …
Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO
G Wingender, N Garbi, B Schumak… - European journal of …, 2006 - Wiley Online Library
CpG‐rich oligonucleotides (CpG‐ODN) bind to Toll‐like receptor 9 (TLR9) and are used as
powerful adjuvants for vaccination. Here we report that CpG‐ODN not only act as immune …
powerful adjuvants for vaccination. Here we report that CpG‐ODN not only act as immune …